FDA sets May 1 deadline for UniQure's Huntington's gene therapy; Inovio's Voceryq approved for RRP; AbbVie wins Botox IRA ...
Regulators issued the hold for Bright Minds' BMB-101 after identifying toxicity issues in preclinical mouse models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results